Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.704%)
Open: 13.75
High: 13.75
Low: 13.75
Prev. Close: 13.75
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

Thu, 04th Jan 2024 16:54

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

The FTSE 100 index closed up 40.74 points, 0.5%, at 7,723.07. The FTSE 250 ended up 45.65 points, 0.2%, at 19,372.05, and the AIM All-Share closed up 1.79 points, or 0.2%, at 755.94.

The Cboe UK 100 ended up 0.6% at 771.71, the Cboe UK 250 closed up 0.6% at 16,874.97, and the Cboe Small Companies ended up 0.5% at 14,940.05.

Stocks in New York were higher at the London equities close, with the DJIA up 0.7%, the S&P 500 index up 0.4%, and the Nasdaq Composite up 0.2%.

Since the new year, eyes have been on the US economy and where interest rates may go in 2024.

On Wednesday evening, investors had the minutes from the latest US Federal Reserve meeting, back in December.

At the December meeting, the rate-setting Federal Open Market Committee agreed to hold its benchmark rate steady in a range between 5.25% and 5.5%. Members indicated that they expect three quarter-percentage point cuts by the end of 2024.

"In discussing the policy outlook, participants viewed the policy rate as likely at or near its peak for this tightening cycle, though they noted that the actual policy path will depend on how the economy evolves," the highly anticipated minutes stated.

Officials "reaffirmed that it would be appropriate for policy to remain at a restrictive stance for some time until inflation was clearly moving down sustainably."

On Thursday, focus has been on the health of the US labour market.

The US labour market added more jobs than expected in December, according to a tracker from payroll processing firm ADP.

ADP said sector employment increased by 164,000 jobs in December, picking up from a 101,000 rise in November and ahead of the FXStreet cited consensus of 115,000. The November total of jobs added was revised from 103,000 to 101,000.

Meanwhile, US new jobless claims fell by more than expected in the most recent week.

According to the US Department of Labor, new jobless claims totalled 202,000 in the week ended December 30. This is down from last week's revised level of 220,000. The latest reading came in lower than FXStreet-cited consensus of 216,000.

The data is out ahead of the US nonfarm payrolls Friday.

Meanwhile, in European equities on Thursday, the CAC 40 in Paris and the DAX 40 in Frankfurt both ended up 0.5%.

According to Destatis, Germany's annual inflation picked up to 3.7%, from 3.2% in November. This came in slightly behind FXStreet market consensus of 3.8%.

Capital Economics' Andrew Kenningham commented: "The jump in Germany's headline inflation rate in December came as no surprise as it was driven by energy price subsidies introduced more than a year ago. With core inflation continuing to trend down, it should not affect investors' expectations for the [European Central Bank] to begin cutting interest rates in the coming months."

The pound was quoted at USD1.2696 at the London equities close Thursday, up compared to USD1.2646 at the close on Wednesday. The euro stood at USD1.0961 at the European equities close Thursday, higher against USD1.0915 at the same time on Wednesday. Against the yen, the dollar was trading at JPY144.48, up compared to JPY143.50 late Wednesday.

In the FTSE 100, retailers Next and JD Sports were the best and worst performing blue-chip stocks respectively, after both provided trading updates including the Christmas period.

JD Sports Fashion plummeted 23%, after cutting its profit outlook amid weaker-than-expected sales growth and gross margins.

The retailer said organic revenue was up 6.0% in the 22 weeks that ended December 30 on a constant currency basis from a year earlier, with like-for-like growth of 1.8%. This was slightly behind its expectations. The retailer expects organic revenue growth of around 8% for the year ending February 3.

As a result, it expects to report pretax profit and adjusted items of between GBP915 million and GBP935 million for the financial year. This falls short of market expectations of GBP1.04 billion, which back in September, JD Sports had said it expected to meet.

Next rose 5.5%, on the back of its trading update.

"Clothing retailer Next has set the bar high for the rest of the retail sector by posting a strong trading update this morning," Edison analyst Russell Pointon commented.

In the nine weeks to December 30, the clothing and homewares seller's full price sales were 5.7% higher year-on-year, some GBP38 million better than its previous guidance. It had expected growth of 2.0% year-on-year. The period forms part of its fourth quarter, which concludes on January 27.

The company now expects pretax profit for financial 2024 of GBP905 million, a lift of GBP20 million from its previous outlook, and it would represent a year-on-year increase of 4.0%. Next had initially expected pretax profit of GBP795 million, but it has, now on a number of occasions, lifted its bottom line outlook.

Meanwhile, BP and Shell rose 0.5% and 0.2%, respectively, as oil prices extended their recent upward movements on concerns over the Middle East.

"The region remains a tinder box due to the Israel-Gaza war, and disruption to shipping routes through the Red Sea is also a key factor behind the surge in crude," AJ Bell's investment director Russ Mould explained.

Brent oil was quoted at USD76.60 a barrel at the London equities close Thursday, down from USD78.13 late Wednesday. Over the last week the price has hit highs of USD79.83.

On London's AIM, Angle shares more than doubled to 31.40 pence.

The Surrey-based medical diagnostics provider celebrated "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Gold was quoted at USD2,0445.01 an ounce at the London equities close Thursday, up against USD2,038.89 at the close on Wednesday.

In Friday's UK corporate calendar, MTI Wireless Edge will hold its extraordinary general meeting regarding proposed grant of options to the directors.

The economic calendar for Friday has eurozone inflation readings at 1000 GMT. Before that, there is the UK Halifax house price index at 0700 GMT.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
13 Dec 2013 11:41

ANGLE sells Geomerics business to ARM Holdings

Specialist medtech company ANGLE has raised 6.2m pounds after realising its investment in graphics technology developer Geomerics, which it sold to ARM Holdings. The group said the additional financial resources will be used within its Parsortix non-invasive cancer diagnostics business, enabling i

Read more
13 May 2013 14:34

Angle shares jump on cell harvesting update

Shares in Angle, a specialist medtech company, leapt 20 per cent on Monday after the group said it has extended the operational capability of its Parsortix non-invasive cancer diagnostic product by automating its cell harvesting function. Harvesting is where captured tumour cells are recovered from

Read more
28 Feb 2013 13:36

Angle initiates launch of cancer diagnostic product for market research

Angle, an AIM-listed specialist medtech company, has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market. The product is based on taking a blood test, and the system either counts circulating tumour cells (CTCs) in the blood or captures and recovers

Read more
31 Jan 2013 13:13

Angle raises funds with placing

Angle, a specialist medtech company, has placed 4.53m new ordinary shares at 50p each, representing a discount of 17.4 per cent on the mid-price of 60.50p per share at close of business on Wednesday. Net of costs, the placing raised £2.2m, which will be used to strengthen the company's financial p

Read more
15 Jan 2013 08:47

Angle jumps again after pay out

Medical technology firm Angle saw its shares jump for a second day in a row after it received cash due from the sale of its portfolio company Acoylte Biomedica. The 2007 sale led to a legal case over an earn-out provision, which saw former Acolyte shareholder, Porton Capital, take the buyer, 3M, to

Read more
14 Jan 2013 09:46

Angle gains on breakthrough in cancer diagnostic technology

Angle advanced more than 90 per cent Monday after the medtech company announced a major breakthrough in its cancer diagnostic product Parsotix. The AIM listed company said it had edged further in the development of Parsortix, a non-invasive technology which captures and counts rare circulating tu

Read more
10 Dec 2012 15:01

Sharp drop in Angle shares following business update

AIM-listed medtech company Angle revealed that Origio, a partner involved in the development of a technology patented as EmbryoSure, has decided to cease EmbryoSure studies in a business update on Monday. EmbryoSure is a technology being developed to assess the viability of embryos for transfer in

Read more
7 Jun 2012 13:59

Small caps round-up: Cyan, Aer Lingus, Mobile Tornado ...

Cyan Holdings, the wireless solutions company, has revealed that three more Cyan partners have received requests from the Tamil Nadu Electricity Board (TNEB) Automatic Meter Reading tender to proceed with installation and commissioning of 500 unit pilots within the next 25 days. The news follows Cya

Read more
30 Apr 2012 08:47

Small caps round-up: Westminster Group, Angle, Asterand

Defence technology firm Westminster Group said its investment in a West African airport was looking promising and that an initial aggregate $150m revenue forecast could be achieved by the contract's eight year break point rather than the full contract term of 15 years. "Should that be the case, the

Read more
23 Apr 2012 14:31

Small caps round up: Intandem, Digital Learning, Hornby ...

Intandem Films, the London and Los Angeles based international film group, will co-produce 10 Things I Hate About Life, and sell the film internationally. The company will also distribute the film in the UK. The script has been written and the film will be directed by Gil Junger, the director of the

Read more
17 Apr 2012 10:40

Angle success with ovarian cancer

Shares in technology investment firm Angle rose on Tuesday after it said its Parsortix cell separation device had passed an important milestone. The firm said that the device could now capture ovarian cancer cells, creating the possibility of developing an effective, non-invasive screening techniqu

Read more
11 Apr 2012 09:46

Small caps round-up: Top Level Domain, Transense, SkyePharma

Top Level Domain Holdings, which operates generic top-level domains, has revealed that is wholly-owned subsidiary, Minds and Machines, has been appointed by Dot London Domains (DLD), the official promotional organisation for London, to assist with DLD's application for the position of registry opera

Read more
15 Mar 2012 12:06

Small caps round-up: HMV, Corero, ANGLE ...

HMV Group, the struggling entertainment media seller, has confirmed that it is still pondering what to do with its live music business. HMV added that a number of parties have indicated an interest in acquiring the business. There has been press speculation recently about who might be interested in

Read more
26 Jan 2012 13:10

Angle raises £1.2m, swings to a half-year loss

Technology investment company ANGLE has raised £1.2m through a fundraising on the same that it revealed it had swung to a loss in the first half ended October 31st. The firm said on Thursday that investors will acquire up to 1,715,717 new ordinary shares in the company at a price of 70p per shar

Read more
23 Jan 2012 14:25

Angle makes important step in cancer technology

Angle's 90%-owned portfolio company, Parsortix, which specialises in medical diagnostics, has used its cell separation device to successfully capture circulating tumour cells (CTCs) in cancer patient blood. The Parsortix separation technology has already been used to capture cultured breast cancer

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.